These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 8822963)

  • 1. Is there an increased risk of graft-versus-host disease after allogeneic peripheral blood stem cell transplantation?
    Koc H; Gürman G; Arslan O; Ozcan M; Akan H; Ilhan O; Konuk N; Beksaç M; Uysal A
    Blood; 1996 Sep; 88(6):2362-4. PubMed ID: 8822963
    [No Abstract]   [Full Text] [Related]  

  • 2. CD34 stem cell dose and development of extensive chronic graft-versus-host disease.
    Handgretinger R; Lang P; Klingebiel T; Niethammer D
    Blood; 2002 May; 99(10):3875-6; author reply 3876-7. PubMed ID: 12014372
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of CD34 cell dose on acute graft versus host disease after allogeneic bone marrow stem cell transplantation.
    Damiani D; Sperotto A; Geromin A; Stocchi R; Fanin R
    Leuk Lymphoma; 2002 Nov; 43(11):2245-7. PubMed ID: 12533058
    [No Abstract]   [Full Text] [Related]  

  • 4. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher CD34(+) and CD3(+) cell doses in the graft promote long-term survival, and have no impact on the incidence of severe acute or chronic graft-versus-host disease after in vivo T cell-depleted unrelated donor hematopoietic stem cell transplantation in children.
    Kałwak K; Porwolik J; Mielcarek M; Gorczyńska E; Owoc-Lempach J; Ussowicz M; Dyla A; Musiał J; Paździor D; Turkiewicz D; Chybicka A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1388-401. PubMed ID: 20382248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.
    Cornelissen JJ; van der Holt B; Petersen EJ; Vindelov L; Russel CA; Höglund M; Maertens J; Schouten HC; Braakman E; Steijaert MM; Zijlmans MJ; Slaper-Cortenbach I; Boogaerts MA; Löwenberg B; Verdonck LF
    Exp Hematol; 2003 Oct; 31(10):855-64. PubMed ID: 14550800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autologous graft-versus-host disease.
    Hess AD
    J Hematother Stem Cell Res; 2000 Jun; 9(3):297. PubMed ID: 10894350
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34(+) cells.
    Miura Y; Ueda M; Takami A; Shiobara S; Nakao S; Hess AD
    Bone Marrow Transplant; 2003 Oct; 32(8):785-90. PubMed ID: 14520422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic transplantation of positively selected peripheral blood CD34+ progenitor cells from matched related donors.
    Finke J; Brugger W; Bertz H; Behringer D; Kunzmann R; Weber-Nordt RM; Kanz L; Mertelsmann R
    Bone Marrow Transplant; 1996 Dec; 18(6):1081-6. PubMed ID: 8971376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD34 positive selection as prophylaxis against graft versus host disease in allogeneic peripheral blood stem cell transplantation.
    Butt NM; McGinnity N; Clark RE
    Leuk Lymphoma; 2003 Sep; 44(9):1509-13. PubMed ID: 14565652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High risk of chronic graft-versus-host disease in unmanipulated allogeneic peripheral blood stem cell transplantation.
    Kalayoğlu-Beşişik S; Budak-Alpdoğan T; Nuri Yenerel M; Sargin D; Tangün Y
    Blood; 1998 Oct; 92(8):2973-5. PubMed ID: 9763587
    [No Abstract]   [Full Text] [Related]  

  • 13. Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndrome: Comparison of Outcomes between CD34
    Tamari R; Oran B; Hilden P; Maloy M; Kongtim P; Papadopoulos EB; Rondon G; Jakubowski AA; Andersson BS; Devlin SM; Ahmed S; Popat UR; Ponce D; Chen J; Sauter C; Young JW; de Lima M; Perales MA; O'Reilly RJ; Giralt SA; Champlin RE; Castro-Malaspina H
    Biol Blood Marrow Transplant; 2018 May; 24(5):1079-1087. PubMed ID: 29325829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Both genetic and clinical factors predict the development of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Socié G; Loiseau P; Tamouza R; Janin A; Busson M; Gluckman E; Charron D
    Transplantation; 2001 Aug; 72(4):699-706. PubMed ID: 11544434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
    Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
    Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation.
    Kanate AS; Craig M; Cumpston A; Saad A; Hobbs G; Leadmon S; Bunner P; Watkins K; Bulian D; Gibson L; Abraham J; Remick SC; Hamadani M
    Hematol Oncol Stem Cell Ther; 2011; 4(4):149-56. PubMed ID: 22198185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transplantation of highly purified peripheral blood CD34+ cells from HLA-mismatched parental donors in 14 children: evaluation of early monitoring of engraftment.
    Peters C; Matthes-Martin S; Fritsch G; Holter W; Lion T; Witt V; Höcker P; Fischer G; Dieckmann K; Handgretinger R; Klingebiel T; Gadner H
    Leukemia; 1999 Dec; 13(12):2070-8. PubMed ID: 10602431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Allogeneic transplantation of peripheral blood progenitor cells.
    Link H; Arseniev L
    Ann Oncol; 1996; 7 Suppl 2():41-5. PubMed ID: 8805948
    [No Abstract]   [Full Text] [Related]  

  • 20. Stem-cell dose for allogeneic hematopoietic stem cell transplantation in hematological malignancies: is more better?
    Shimoni A; Nagler A
    Leuk Lymphoma; 2009 Sep; 50(9):1395-6. PubMed ID: 19672777
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.